These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34299405)

  • 1. Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug-Design and Mechanism of Action.
    Buric AJ; Dickerhoff J; Yang D
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944.
    Lin C; Yang D
    Curr Top Med Chem; 2015; 15(14):1385-97. PubMed ID: 25866279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological characterization of MLN944: a potent DNA binding agent.
    Sappal DS; McClendon AK; Fleming JA; Thoroddsen V; Connolly K; Reimer C; Blackman RK; Bulawa CE; Osheroff N; Charlton P; Rudolph-Owen LA
    Mol Cancer Ther; 2004 Jan; 3(1):47-58. PubMed ID: 14749475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solution structure of a 2:1 complex of anticancer drug XR5944 with TFF1 estrogen response element: insights into DNA recognition by a bis-intercalator.
    Lin C; Mathad RI; Zhang Z; Sidell N; Yang D
    Nucleic Acids Res; 2014 May; 42(9):6012-24. PubMed ID: 24711371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug.
    Dai J; Punchihewa C; Mistry P; Ooi AT; Yang D
    J Biol Chem; 2004 Oct; 279(44):46096-103. PubMed ID: 15317822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intercalation of XR5944 with the estrogen response element is modulated by the tri-nucleotide spacer sequence between half-sites.
    Sidell N; Mathad RI; Shu FJ; Zhang Z; Kallen CB; Yang D
    J Steroid Biochem Mol Biol; 2011 Apr; 124(3-5):121-7. PubMed ID: 21333738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944.
    Lewis LJ; Mistry P; Charlton PA; Thomas H; Coley HM
    Anticancer Drugs; 2007 Feb; 18(2):139-48. PubMed ID: 17159600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XR5944: A potent inhibitor of estrogen receptors.
    Punchihewa C; De Alba A; Sidell N; Yang D
    Mol Cancer Ther; 2007 Jan; 6(1):213-9. PubMed ID: 17218634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.
    Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Sharma S; Charlton PA; Norris D; Cree IA
    Mol Cancer Ther; 2004 Dec; 3(12):1631-7. PubMed ID: 15634657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structures and dynamics of DNA complexes of the desmethyl analog of the cytotoxin MLN944: Insights into activity when a methyl isn't futile.
    Serobian A; Pracey CP; Thomas DS; Denny WA; Ball GE; Wakelin LPG
    J Mol Recognit; 2020 Aug; 33(8):e2843. PubMed ID: 32253794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,8-Naphthalimide: A Potent DNA Intercalator and Target for Cancer Therapy.
    Tandon R; Luxami V; Kaur H; Tandon N; Paul K
    Chem Rec; 2017 Oct; 17(10):956-993. PubMed ID: 28375569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma.
    Harris SM; Scott JA; Brown JL; Charlton PA; Mistry P
    Anticancer Drugs; 2005 Oct; 16(9):945-51. PubMed ID: 16162971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: a potential anti-protozoa and anti-tumor agent.
    Benítez J; Guggeri L; Tomaz I; Pessoa JC; Moreno V; Lorenzo J; Avilés FX; Garat B; Gambino D
    J Inorg Biochem; 2009 Oct; 103(10):1386-94. PubMed ID: 19695708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation.
    Baruah H; Barry CG; Bierbach U
    Curr Top Med Chem; 2004; 4(15):1537-49. PubMed ID: 15579095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiproliferative agent MLN944 preferentially inhibits transcription.
    Byers SA; Schafer B; Sappal DS; Brown J; Price DH
    Mol Cancer Ther; 2005 Aug; 4(8):1260-7. PubMed ID: 16093442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative QSAR studies on substituted bis-(acridines) and bis-(phenazines)-carboxamides: a new class of anticancer agents.
    Garg R; Denny WA; Hansch C
    Bioorg Med Chem; 2000 Jul; 8(7):1835-9. PubMed ID: 10976532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and anticancer properties of a novel bis-intercalator.
    Shen W; Deng H; Gao Z
    Anticancer Agents Med Chem; 2013 May; 13(4):632-8. PubMed ID: 22931414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spermine attenuates the action of the DNA intercalator, actinomycin D, on DNA binding and the inhibition of transcription and DNA replication.
    Wang SY; Lee AY; Lai YH; Chen JJ; Wu WL; Yuann JM; Su WL; Chuang SM; Hou MH
    PLoS One; 2012; 7(11):e47101. PubMed ID: 23144800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
    Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.